Home » Stocks » PGNX

Progenics Pharmaceuticals, Inc. (PGNX)

Jun 19, 2020 - PGNX was delisted (reason: acquired by LNTH)
Stock Price: $4.10 USD -0.43 (-9.49%)
Updated Jun 19, 2020 4:00 PM EDT
Market Cap 355.05M
Revenue (ttm) 36.95M
Net Income (ttm) -66.62M
Shares Out 86.60M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Jun 19, 2020
Last Price $4.10
Previous Close $4.53
Change ($) -0.43
Change (%) -9.49%
Day's Open -
Day's Range 3.94 - 4.79
Day's Volume 0
52-Week Range 1.89 - 6.37

News

Hide News
GlobeNewsWire - 7 months ago

NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to f...

PRNewsWire - 7 months ago

NEW YORK, May 27, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Progenics Pharmaceuticals, Inc...

Seeking Alpha - 8 months ago

Progenics Pharmaceuticals' (PGNX) CEO David Mims on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 11 months ago

Progenics: Ready To Decouple From Lantheus After PyL Data

GlobeNewsWire - 11 months ago

NEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artifici...

Market Watch - 1 year ago

Progenics Pharmaceuticals, Inc. PGNX, -1.34% said Monday a late-stage trial of a treatment for prostate cancer met its main goal.

GlobeNewsWire - 1 year ago

- Met Primary Endpoint With a Correct Localization Rate of 84.8–87.0%, Highlighting Strong Diagnostic Performance - Company Expects to Submit an NDA to the FDA in the Second Half of 2020 ...

GlobeNewsWire - 1 year ago

NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, f...

GlobeNewsWire - 1 year ago

NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and art...

Zacks Investment Research - 1 year ago

Progenics (PGNX) delivered earnings and revenue surprises of 18.52% and -20.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Progenics (PGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

November 17 is the Only Deadline for Velan’s Consent Solicitation

GlobeNewsWire - 1 year ago

Notifies Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17

GlobeNewsWire - 1 year ago

ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company

GlobeNewsWire - 1 year ago

Flags Velan’s Knowledge of Lantheus Transaction Weeks Before It Was Made Public

GlobeNewsWire - 1 year ago

Calls Out Velan’s Pattern of Disregard for Good Corporate Governance and Business Ethics

Benzinga - 1 year ago

Micro-cap biotech Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) is advancing strongly following an announcement concerning a buyout deal.

Other stocks mentioned: LNTH
GlobeNewsWire - 1 year ago

Board Has Made Numerous Corporate Governance Enhancements Reflecting Feedback From Shareholders

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) an oncology company developing innovative targeted medicines and artificial intelligence to find, f...

Seeking Alpha - 1 year ago

Progenics recently reported their Q2 earnings with a miss on EPS and a beat on revenue. However, Velan Capital is not impressed and released their assessment of the quarter.

Seeking Alpha - 1 year ago

Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Baker on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Progenics (PGNX) delivered earnings and revenue surprises of -9.52% and 55.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

CytoDyn is moving their PRO 140 product candidate closer towards an FDA approval in HIV. I recall how I discovered CYDY and my plans for starting a speculative position.

Seeking Alpha - 1 year ago

Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Baker on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Progenics (PGNX) delivered earnings and revenue surprises of 8.33% and 15.39%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Despite the subpar data regarding 1404 and PyL, Progenics Pharmaceuticals is undergoing strong fundamental improvement.

Zacks Investment Research - 1 year ago

Progenics (PGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

I have been hesitant about buying into Progenics Pharmaceuticals due to my insufficient knowledge about the advancements of radiopharmaceuticals in the oncology arena.

Seeking Alpha - 1 year ago

Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Baker on Q4 2018 Results - Earnings Call Transcript

About PGNX

Progenics Pharmaceuticals, an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-target... [Read more...]

Industry
Biotechnology
IPO Date
Nov 19, 1997
CEO
David W. Mims
Employees
105
Stock Exchange
NASDAQ
Ticker Symbol
PGNX
Full Company Profile

Financial Performance

In 2019, PGNX's revenue was $34.99 million, an increase of 123.95% compared to the previous year's $15.62 million. Losses were -$68.55 million, 1.32% more than in 2018.

Financial Statements